Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity

Table 2

IMK ATP levels in the patients who experienced late clinical events.

Age	Gender	Etiology of LDLT	Clinical events	Months after LDLT	Tacrolimus; concentration; (ng/mL)	C/D ratio; (ng/mL/mg/kg/day)	IMK; ATP levels (ng/mL)
46	F	LC	Phlegmon	89.5	9.8	99.76	112
60	M	LC	Cholangitis	103.3	8.4	478.80	113
58	M	HCV, HCC	RHC	57.9	6.3	43.31	137
20	F	PSC	Cholangitis	92.1	3.9	105.86	141
60	M	HCV	RHC	27.1	8.2	259.12	149
61	F	LC, HCC	UTI	34.9	10	229.00	166
68	M	HCV, HCC	RHC	52.4	7.9	166.95	205
62	F	HCV, HCC	RHC	86.3	8.6	237.79	215
52	M	PBC	Pneumonia	55.5	2.7	316.44	222
50	M	HCV	RHC	17.3	2.0	128.80	322
51	M	PBC	Rejection	38.8	2.5	43.25	569
43	M	FH	Rejection	45.4	8.4	171.57	683
58	F	HBV, HCC	Rejection	19.9	9.9	207.90	692
25	M	BA	Rejection	104.7	6.8	113.33	709

IMK: ImmuKnow, LDLT: living donor liver transplantation, C/D ratio: concentration/dosage ratio, LC: liver cirrhosis, HCV: hepatitis C virus, HCC: hepatocellular carcinoma, PSC: primary sclerosing cholangitis, PBC: primary biliary cirrhosis, HBV: hepatitis B virus, FH: fulminant hepatitis, BA: biliary atresia, RHC: recurrence of hepatitis C, UTI: urinary tract infection.